ArticleActa radiologica open2026
Intraoperative MRI for giant cell tumor of bone after denosumab and other selected tumors: A pilot study.
Article in Acta radiologica open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although intraoperative magnetic resonance imaging (iMRI) is well established in neurosurgery, its role in musculoskeletal oncology remains unclear. Purpose: To assess the feasibility and safety of iMRI in bone and soft tissue tumor surgery, focusing on giant cell tumor of bone (GCTB) after denosumab. Material and Methods: Fourteen patients (12 GCTB, 1 undifferentiated pleomorphic sarcoma [UPS], 1 chondroblastoma) underwent tumor resection with intraoperative 0.4 T MRI between 2017 and 2024. Outcomes included residual tumor detection, recurrence, and safety. Results: iMRI identified residual tumor in 7 of 12 GCTB patients (58.3%), all histologically confirmed. At a median follow-up of 42 months, recurrence occurred in one GCTB case (8.3%). iMRI guided complete resection in a femoral head chondroblastoma, enabling full functional recovery. Soft tissue assessment was limited in the UPS case. No iMRI-related complications occurred. Conclusion: iMRI is a feasible and safe adjunct in bone tumor surgery, enhancing detection of residual tumor and supporting joint-preserving procedures, particularly in GCTB after denosumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.